Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus IOPAMIDOL 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 IN PLASTIC CONTAINER versus IOPAMIDOL 370.
IOPAMIDOL-250 IN PLASTIC CONTAINER vs IOPAMIDOL-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Iopamidol is a nonionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. Its mechanism is physical rather than pharmacological, based on iodine content and osmolality.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
1-2 mL/kg (370 mg iodine/mL) IV up to a maximum of 150 mL per procedure for contrast-enhanced CT; for angiography, dose varies by procedure.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Terminal elimination half-life is approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function. Prolonged to 10-70 hours in patients with renal impairment, necessitating dose adjustment or avoidance.
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal; >90% of administered dose excreted unchanged in urine via glomerular filtration within 24-48 hours. Less than 1% excreted in feces or bile.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent